Dermavant Sciences GmbH

Dermavant Sciences GmbH logo
🇨🇭Switzerland
Ownership
Subsidiary
Established
2016-01-01
Employees
251
Market Cap
-
Website
https://dermavant.com
Clinical Trials
Related News

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

Phase 2
Completed
Conditions
Vitiligo
Interventions
Drug: Cerdulatinib 0.37% gel
Drug: Vehicle gel
First Posted Date
2019-09-25
Last Posted Date
2020-11-24
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
33
Registration Number
NCT04103060
Locations
🇺🇸

Dermavant Investigational Site, Worcester, Massachusetts, United States

Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)

Phase 3
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: tapinarof cream, 1%
First Posted Date
2019-08-12
Last Posted Date
2022-09-29
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
763
Registration Number
NCT04053387
Locations
🇨🇦

Dermavant Investigative Site, Montréal, Quebec, Canada

🇨🇦

Dermavant Clinical Site, Markham, Ontario, Canada

🇺🇸

Dermavant Investigational Site, Detroit, Michigan, United States

and more 1 locations

Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis

Phase 2
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: Tapinarof cream, 1%
First Posted Date
2019-08-01
Last Posted Date
2022-05-06
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
21
Registration Number
NCT04042103
Locations
🇺🇸

Dermavant Investigational Site, Spokane, Washington, United States

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)

Phase 3
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: Vehicle Cream
Drug: Tapinarof
First Posted Date
2019-06-12
Last Posted Date
2022-10-13
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
515
Registration Number
NCT03983980
Locations
🇨🇦

Dermavant Investigative Site, Ottawa, Ontario, Canada

Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

Phase 3
Completed
Conditions
Plaque Psoriasis
Interventions
Drug: Vehicle Cream
Drug: Tapinarof
First Posted Date
2019-05-20
Last Posted Date
2022-10-13
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
510
Registration Number
NCT03956355
Locations
🇨🇦

Dermavant Investigative Site, Montréal, Quebec, Canada

Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

First Posted Date
2018-01-30
Last Posted Date
2018-05-11
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
24
Registration Number
NCT03415282
Locations
🇺🇸

Dermavant Investigational Site, Richmond, Virginia, United States

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

First Posted Date
2018-01-09
Last Posted Date
2018-07-19
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
110
Registration Number
NCT03394677
Locations
🇨🇦

Dermavant Investigational Site, Montreal, Quebec, Canada

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

First Posted Date
2016-11-01
Last Posted Date
2018-08-06
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
157
Registration Number
NCT02950922
Locations
🇨🇦

Dermavant Investigator Site, Waterloo, Ontario, Canada

🇨🇦

Dermavant Investigational Site, Montreal, Quebec, Canada

A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis

First Posted Date
2014-03-21
Last Posted Date
2018-03-01
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
62
Registration Number
NCT02094235

A Phase 2 Study of E6005 in Patients With Atopic Dermatitis

Phase 2
Completed
Conditions
Atopic Dermatitis
Interventions
Drug: E6005
Drug: E6005 ointment (vehicle)
First Posted Date
2011-10-28
Last Posted Date
2018-03-01
Lead Sponsor
Dermavant Sciences GmbH
Target Recruit Count
78
Registration Number
NCT01461941
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy